Physician profile
Roberto A Cano
NPI 1164488110
$2,205.14
in general payments reported to CMS, 2019-2025
26 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $43.60 · 2021: $108 · 2022: $167 · 2023: $727 · 2024: $632 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.97 |
| Education | $178.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $727.35 | 2019-2025 | Darzalex, Carvykti, Rybrevant |
| Novartis Pharmaceuticals Corporation | $287.62 | 2019-2025 | |
| Incyte Corporation | $253.84 | 2022-2025 | Monjuvi, Zynyz, Jakafi |
| Celgene Corporation | $169.44 | 2019-2025 | Reblozyl |
| Adaptive Biotechnologies Corporation | $99.64 | 2023-2025 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $73.20 | 2019 | |
| Rigel Pharmaceuticals, INC. | $57.58 | 2023-2024 | Rezlidhia, Tavalisse |
| Pfizer INC. | $48.05 | 2022-2024 | |
| Eisai INC. | $44.62 | 2023-2024 | |
| Genzyme Corporation | $44.26 | 2024 | |
| Myriad Genetic Laboratories, INC. | $42.88 | 2024 | Myrisk |
| Genentech USA, INC. | $42.60 | 2023 | Columvi, Polivy, Lunsumio |
| Daiichi Sankyo INC. | $37.26 | 2023 | Enhertu |
| Seagen INC. | $27.26 | 2023 | Adcetris |
| Glaxosmithkline, LLC. | $26.90 | 2023 | Ojjaara |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $24.82 | 2025 | Rytelo |
| Astrazeneca Pharmaceuticals Lp | $24.57 | 2023 | Tagrisso |
| Abbvie INC. | $23.96 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.46 | 2024 | Somatuline Depot, Onivyde |
| Apellis Pharmaceuticals, INC. | $21.36 | 2025 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $21.06 | 2024 | |
| Beigene USA, INC. | $20.50 | 2024 | Brukinsa |
| Janssen Pharmaceuticals, INC | $20.14 | 2019 | |
| Amgen INC. | $15.64 | 2023 | Kyprolis, Blincyto |
| Abbott Laboratories | $14.94 | 2023 | Aveir |
| Beone Medicines USA, INC. | $14.19 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Cano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.